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Vaccines effectively reduce and prevent
death and disease from many viral infections.
However, vaccine production occasionally has
been complicated by inadvertent contamination
with adventitious agents that may have
originated from cell substrates used to propagate
vaccine strains. Examples of such contamination
include simian virus in early polio vaccines
grown on monkey kidney cells and avian leukosis
virus (ALV) in yellow fever vaccines propagated
in chick embryos (1). Hepatitis B virus has also
been identified in yellow fever vaccines produced
by using pooled human serum as a stabilizing
agent (2). Exposure of vaccine recipients to
contaminated vaccines has been associated with
effects ranging from benign to demonstrable
transmission of infection, with or without
subsequent disease (2,3).
Reverse transcriptase (RT) activity, an
indicator of retroviruses, has recently been
detected by sensitive polymerase chain reaction
(PCR)-based RT assays in currently used
vaccines produced in chick embryo fibroblasts or
embryonated eggs (4-7). The RT-positive vac-
cines include measles, mumps, and yellow fever
vaccines produced by several manufacturers in
Europe and the United States (4,5). RT activity
was detected in the vaccines despite strict
manufacturing practices requiring that chick
embryos and embryo fibroblasts be derived from
closed, specific-pathogen-free chicken flocks.
Such chickens are screened for known pathogens,
including two exogenous avian retroviruses:
reticuloendotheliosis virus and ALV (8).
The origin of RT activity in measles vaccines
was examined in two recent studies. RT activity
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in a vaccine manufactured in Europe was
associated with particles containing endogenous
avian virus (EAV) RNA (6). In the second study,
we examined measles vaccines from a U.S.
manufacturer and found evidence of both EAV
and endogenous ALV (7): we detected particle-
associated ALV and EAV-0 RNA sequences in
both vaccine and chick embryo fibroblast
supernatants and demonstrated neutralization
of RT activity in vaccines by anti-ALV RT
antibodies. In addition, we observed ALV-like
particles by electron microscopy in culture
supernatants from chick embryo fibroblasts that
had not been inoculated with vaccine viruses (7).
At least six subgroups of ALV (A-E and J)
have been identified in chickens on the basis of
differences in envelope sequences (9). Only
subgroup E viruses are expressed from endog-
enous sequences that are part of the chicken
germ line; all the other subgroups are exogenous.
The endogenous ALV sequences are usually
referred to as endogenous viral (ev) loci. At least
30  ev loci have been characterized in various
chicken strains (10). Although endogenous ALVs
are not known to be pathogenic for chickens,
related species of fowl are susceptible to infection
with endogenous ALV (11). Disease associations
in these cross-species infections have not been
fully investigated (11). Exogenous-type ALVs
have been shown to cause several neoplastic
diseases in infected chickens (9).
Less is known about EAV, which has
elements distinct from but closely related to
those of the ALV family of endogenous
retroviruses. EAV are also present in line-0
chickens (ev-negative), which have been bred to
have no ev proviruses (12). EAV elements exist in
at least 50 copies per chicken genome (13).
The observed association of the RT activity of
these vaccines with endogenous retroviral
particles rather than exogenous retroviruses is
consistent with vaccine manufacturing regula-
tions that require exogenous ALV and
reticuloendotheliosis virus infections to be
eliminated from source chickens. Endogenous
retroviral particles are not addressed by current
manufacturing guidelines because these par-
ticles had not been associated with chick cell-
derived vaccines.
The finding of RT activity in all measles
vaccine lots from different manufacturers tested
suggests that this occurrence is not sporadic and
that vaccine recipients may be universally
exposed to these retroviral particles (4,5,7,14).
Surveillance for infection with ALV/EAV in
vaccine recipients is important for evaluating the
safety of these vaccines. This surveillance, which
was recommended by the World Health
Organization in a consultation meeting on RT
activity in chicken cell-derived vaccines, is
needed for policy decisions regarding the global
use of these vaccines (15). We recently reported
negative PCR results for ALV and EAV
sequences in peripheral blood lymphocytes from
33 measles, mumps, and rubella (MMR) vaccine
recipients (7). However, these preliminary
results do not fully reflect risks for transmission
of ALV and EAV because of the small number of
samples analyzed and the lack of testing for
antibodies and plasma viremia (7). We have
expanded our surveillance for ALV and EAV
infection in recipients of MMR vaccines and here
report evidence that does not support infection
with either ALV or EAV.
Materials and Methods
Study Population
The study population was 206 children
identified from two cohorts. Samples for 113 of
the children were identified from repository
serum specimens of the New York City Perinatal
HIV Transmission Collaborative Study and
Perinatal AIDS Collaborative Transmission
Study (PACTS). All 113 children had documented
evidence of MMR vaccination; none were infected
with HIV-1 (16). The remaining 93 children
participated in a study of antibody responses to
immunization with the U.S.-manufactured MMR
vaccine (17). Of 206 specimens analyzed, 32
(15.5%) were collected 6 to 12 months and 158
(76.7%) 12 to 24 months after the first MMR
vaccination. Sixteen (7.8%) samples were
collected after the second MMR dose. Peripheral
blood lymphocytes samples were available for
100 of 113 children from the PACTS study. All
testing was done anonymously with regard to
children’s identity.
Endogenous ALV-based Western Blot Assay
The source of antigen for the Western blot
assay was the Rous-associated virus type 0 (RAV-
0), a prototype endogenous ALV highly related to
the endogenous ALV particles found in MMR
vaccine (9,10,18). RAV-0 was inoculated into
15B1 chick embryo fibroblast cells. Infection with68 Emerging Infectious Diseases Vol. 7, No. 1, January–February 2001
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RAV-0 was monitored by using the ALV antigen
test kit (Flockchek, IDEXX, ME) that detects
ALV p27 gag antigen. Antigen was prepared by
lysing 106 cells with 100 µL lysis buffer, followed
by 5 minutes each of boiling and sonication. The
protein concentration of the lysate was deter-
mined with the Pierce protein kit (Rockford, IL).
Electrophoresis was done on 150 µg of either
infected or uninfected whole-cell lysates in 10%-
20% Tris-HCl gradient SDS-polyacrylamide gels
(BioRad, CA) for 2 hours at 70V. Serum samples
were diluted 1:50 in blocking buffer. Rabbit anti-
avian myeloblastosis virus (AMV, an exogenous
strain of ALV) p27 (SPAFAS, Preston, CT)
antibody was used as positive control. Anti-
rabbit, anti-chicken, and anti-human antibodies
conjugated to horseradish peroxidase were used
as secondary antibodies for rabbit, chicken, and
human plasma samples at 1:6000, 1:3000, and
1:6000 dilutions, respectively. Control human
IgG was used as an assay control for anti-
human horseradish peroxidase-conjugated sec-
ondary antibody.
To validate the Western blot assay, sera from
27 chickens seropositive by virus neutralization
assays for ALV (subgroup A) and 34 ALV-
seronegative chickens were tested for
seroreactivity to ALV antigens by Western blot.
In addition, 10 serum samples from chickens
infected with reticuloendotheliosis virus were
used as specificity controls. Validation on human
sera included testing samples from persons
infected with human T-cell lymphotropic virus
types I and II (HTLV-I and HTLV-II) and HIV
types 1 and 2 to assess possible cross-reactivity
between ALV and human retroviruses. HTLV-
and HIV-negative sera from anonymous blood
donors were also included in this validation. All
chicken serum samples used for validation of the
RAV-0 Western blot assay were also tested on
blots containing control antigen from uninfected
15B1 chick embryo fibroblasts.
Proviral DNA PCR
Aliquots of lysates from 150,000 peripheral
blood lymphocytes from MMR vaccine recipients
were amplified by PCR for ALV env and EAV env-
like sequences by using primers ALVENVF2/
ALVENVR2 and EAVENVF10/EAVENVR10,
respectively (7). All diagnostic primers used were
derived from particle-associated viral sequences
identified in the vaccine substrate used to
prepare the MMR vaccine (7). Both assays are
highly sensitive, with a detection threshold of one
copy for EAV PCR assay and 1-10 copies for the
ALV PCR assay (7). The PCR reaction conditions
included 35 cycles of 95°C for 1 minute, 55°C for 1
minute, and 72°C for 1 minute. PCR products
were detected by Southern blot hybridization to
the ALV- and EAV-specific 32P-labeled probes,
ALVENVP1 and EAVENVP1, respectively (7).
Detection of ALV and EAV RNA
in Vaccine Recipients
RNA was extracted from serum as described
(19). The primers used for the RT reaction were
ALVENVR2 and EAVENVR10 for ALV and EAV,
respectively. The reaction was carried out at 37°C
for 2 hours, followed by 95°C for 5 minutes. RNA
extracted from RAV-0-infected 15B1 chick
embryo fibroblast supernatants was used for
positive controls. PCR was carried out as
described (7). The ALV and EAV PCR products
were detected by Southern blot hybridization
with the 32P-labeled ALVENVP1 and EAVENVP1
probes, respectively.
Results
Validation of Western Blot Assay
 and Criteria for Positivity
The presence of viral proteins was confirmed
by the use of antisera raised against whole ALVs
(anti-AMV and anti-RAV-0) and against anti-p27
gag protein from AMV (Table). These antisera
detected env gp85 and gp37 as well as gag p27,
Table. Western blot antibody reactivity to the p27 gag pro-
tein of the endogenous avian leukosis virus (ALV) in  vac-
cine recipients and other reference chicken and human sera
Sera tested p27 Positive
Chicken sera (n = 61)
  ALV infected/antibody positivea 27/27
  ALV uninfected/antibody negativea 0/34
  REV infected 0/10
Human sera (n = 68)
   Blood donors 0/60
  HIV-1/2 positive 0/4
  HTLV-I/II positive 0/4
MMR vaccine recipients (n = 206)
  6-12 monthsb 0/32
  12-30 monthsb 0/158
  6-12 monthsc 0/16
aantibody reactivity to ALV determined by virus neutralization
assays.
bsamples collected after first MMR vaccination.
csamples collected after second MMR vaccination.
REV = reticuloendotheliosis virus; HIV-1/2 = human immunodefi-
ciency virus type 1 or 2; HTLV-I/II = human T-cell lymphotropic
virus type 1 or 2; MMR = measles, mumps and rubella69 Vol. 7, No. 1, January–February 2001 Emerging Infectious Diseases
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p19, p15, and p12 proteins (data not shown). All
27 ALV-infected and neutralization antibody-
positive chicken sera reacted strongly to RAV-0
p27, while negative control sera from both
uninfected chickens and reticuloendotheliosis
virus-infected chickens showed no reactivity to
p27 (Figure 1a). These data support the use of
p27 reactivity as a marker for ALV seropositivity.
Similarly, negative results were seen with
samples from 60 human blood donors. No cross-
reactivity was observed between RAV-0 p27 gag
protein and antibodies against HIV-1, HIV-2,
HTLV-I, and HTLV-II (data not shown).
Lack of Evidence of Seroreactivity to ALV
Serum samples from all 206 MMR vaccine
recipients were negative by Western blot (Table).
These samples included those of the 16 children
who had received two doses of MMR vaccine
(Figure 1b). No seroreactivity to any viral
proteins, including p27, was observed.
Lack of Evidence of ALV and EAV Sequences
All 100 peripheral blood lymphocyte samples
were negative for both ALV and EAV DNA
sequences by PCR analysis (Figure 2). Of the 100
samples from the PACTS cohort, 33 had been
tested previously (7). Similarly, all sera from the
100 children tested negative for both ALV and
EAV RNA by RT-PCR (Figure 3). These results
indicate  absence of both ALV and EAV viremia in
these vaccine recipients (Table).
Figure 1. Western blot antibody reactivity of chicken
sera to endogenous avian leukosis virus (ALV) (Rous-
associated virus 0) antigen. a) Lane 1, negative control
chicken serum; Lane 2, positive control anti-p27 ALV
gag antiserum; lanes 3-5, sera from ALV antibody-
positive chickens; lanes 6-12, sera from ALV-negative,
antibody-negative chickens. b) NC, negative control
human sera; PC, positive control: anti-p27 ALV gag




Figure 2. Representative results from polymerase
chain reaction analysis of peripheral blood lympho-
cytes from measles, mumps and rubella (MMR)
vaccine recipients for endogenous avian retrovirus
(EAV) (A) and avian leukosis virus (ALV) (B) proviral
DNA sequences. The detection threshold of known
copy numbers of the target sequences is shown in the
righthand panels. NC, negative control, uninfected
human peripheral blood lymphocytes; PC, positive
control, human peripheral blood lymphocytes spiked
with 1,000 copies of target sequence; Lanes 1-10,
peripheral blood lymphocytes from MMR vaccine
recipients.70 Emerging Infectious Diseases Vol. 7, No. 1, January–February 2001
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Conclusions
Analysis of MMR vaccines from different
manufacturers suggests that vaccine recipients
may be universally exposed to endogenous
chicken retroviral particles. We sought evidence
of persistent ALV and EAV infection in a large
number of MMR vaccine recipients, and we were
unable to find any evidence of ALV or EAV
sequences in peripheral blood lymphocytes,
despite the use of highly sensitive PCR assays.
Neither did we find evidence of ALV or EAV
viremia, since all serum samples tested negative
for ALV and EAV RNA by RT-PCR analysis; this
finding is of interest because ALV viremia is
commonly seen in chickens infected with ALV
(18). All 206 serum samples tested by a validated
Western blot assay were negative for ALV
antibodies, indicating absence of antigenic
exposure. These findings differ from those in
persons infected with human retroviruses, who
usually seroconvert 2 weeks to 6 months after
exposure (20,21). The negative serologic data also
suggest the low likelihood of nonviremic ALV
infection in cells other than peripheral blood
lymphocytes, which may not have been detected
by PCR testing. Our results overall show no
evidence of infection with either ALV or EAV in
these vaccine recipients. The lack of transmission
of ALV and EAV observed in 16 children who had
two MMR vaccinations provides additional
reassuring data.
Several factors, including a natural human
resistance to infection with endogenous ALV,
may explain the lack of transmission of these
viruses to MMR vaccine recipients. However, few
or no data are available on the ability of
endogenous ALV to replicate in human cells.
Resistance to endogenous ALV infection may, for
instance, be attributed to the absence of a human
cell-surface receptor for the virus as well as to
other intracellular blocks for ALV replication. A
tumor necrosis factor receptor-related protein,
referred to as SEAR, has been recently identified
as a receptor for endogenous ALV in turkey cells
(22). Plasmid-encoded expression of SEAR in
human 293 cells can confer susceptibility to
infection by endogenous ALV, suggesting that
human cells can support endogenous ALV
replication if virus entry is achieved (22). Human
serum can lyse ALV by complement activation
(23); however, this protective mechanism has not
been demonstrated for endogenous ALV and EAV
particles.
The presence of defective ALV and EAV
particles in vaccines may also explain the lack of
transmission of these viruses to vaccine
recipients. ev loci confer a variety of different
phenotypes, including infectious or defective
particles (9,10,18,24). However, it is not known
whether the ALV particles in the vaccine are all
defective. The proportion of defective to
infectious ALV in different vaccine lots depends
on the set of the ev loci in the chick embryo
fibroblast substrate preparation used for each
vaccine lot. Loci associated with noninfectious
viruses (ev-1, ev-3, and ev-6) have been identified
in a chick embryo fibroblast substrate of a U.S.
vaccine manufacturer (7). However, the presence
of many loci known to produce infectious ALV-E
could not be determined (7).
EAV may represent the predominant
retroviral particles in MMR vaccines (6,7).
Therefore, our data, which indicate that exposure
to EAV particles was not associated with EAV
viremia or EAV-infected peripheral blood
lymphocytes in vaccine recipients, are important.
Confirmation of our molecular results by EAV-
specific serologic testing may, however, be
necessary. The lack of evidence of transmission of
Figure 3. Reverse transcriptase-polymerase chain
reaction analysis of sera from measles, mumps and
rubella (MMR) vaccine recipients for the presence of
avian leukosis virus (ALV) (A) and endogenous avian
retrovirus (EAV) (B) RNA. Lanes 1-10, samples from
MMR vaccine recipients. NC, negative control,
uninfected human serum; PC, positive control, culture
supernatant from Rous-associated virus 0 (RAV-0)
infected 15B1 chick embryo fibroblasts.71 Vol. 7, No. 1, January–February 2001 Emerging Infectious Diseases
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EAV to vaccinees is likely due to the presence of
defective particles. No infectious EAVs have yet
been isolated, nor has a full-length intact EAV
provirus been identified (25). However, our
understanding of the EAV family is limited.
The presence of ALV in chick-cell-derived
vaccines is not a new phenomenon; many
instances of ALV contamination in yellow fever
and measles vaccines have been documented
(26,27). However, earlier vaccines had evidence
of exogenous rather than endogenous type ALV
(27). Available data also suggest lack of
transmission of ALV to vaccine recipients
(26,28,29). These studies examined 6 adults and
41 children with measles vaccination and 227
yellow fever vaccine recipients (26,27,29), and no
evidence was found of neutralizing antibodies to
an exogenous ALV. No increase in cancer rate has
been found in a study of recipients of exogenous
ALV-positive yellow fever vaccine (27).
Despite these reassuring data, the presence
of avian retroviral particles in chick embryo
fibroblast-derived vaccines raises questions
about the suitability of primary chicken cell
substrates for vaccine production and the
advisability of a change to RT-negative sub-
strates. Chick embryo fibroblasts originating
from line 0 chickens could provide substrates
that do not express ALV-E; however, such cells
may still produce EAV particles (7,12). Obtaining
an RT-negative substrate may require a
substantial change from primary chicken cells to
RT-negative cells from different species, such as
immortalized or diploid mammalian cells. Since
the cell substrate is critical to the attenuation of
live vaccine viruses, any change in the cell
substrate could have unpredictable effects on the
safety and efficacy of the vaccine and should be
approached cautiously.
In conclusion, we found no evidence of either
endogenous ALV or EAV infection in recipients of
U.S.-made MMR vaccines. Our data indicate that
no change is warranted in current U.S. policies
for the use of MMR vaccine.
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